NEW YORK (GenomeWeb News) — BioMérieux said today the US Food and Drug Administration has cleared its in vitro diagnostic that tests for a patient’s risk of developing severe sepsis and septic shock.
 
The company said its VIDAS B.R.A.H.M.S. PCT assay is designed to help assess the risk that a critically ill patient with a bacterial infection faces of developing severe sepsis or septic shock.
 
BioMérieux launched the assay in Europe earlier this year.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study in JAMA finds that genetic tests might not be able to determine what diet is right for someone seeking to lose weight.

Vampire bats' ability to live off blood is etched in their genomes and gut microbiomes, the Scientist reports.

A genome-wide association study that linked common genetic variants to salivary gland carcinoma risk has been retracted, according to Retraction Watch.

In Genome Biology this week: peopling of the Sahara, epigenetic reprogramming analysis of liverwort, and more.